| 1 | Probing proton halo of the exotic nucleus ^(28)S by elastic electron scattering显示文摘Elastic electron scattering on the exotic light nucleus 28S is investigated in the plane wave Born approximation. The variation of the squared form factors of 28S with momentum transfer is compared with that of 32S. It is found that the behavior of the form factors near the second minimum (with a moderate momentum transfer) is sensitive to the alteration of the charge density distribution of halo protons in 28S. This indicates that elastic electron scattering can be a good probe of the structure of proton-halo nuclei. | WANG Zaijun1 & REN Zhongzhou1’2 1. Department of Physics, Nanjing University, Nanjing 210008, China 2. Center of Theoretical Nuclear Physics, National Laboratory of Heavy-Ion Accelerator at Lanzhou, Lanzhou 730000, China Correspondence should be addressed to Ren Zhongzhou (email: zren@nju.edu.cn zren99@yahoo.com) Received June 16, 2003 | 2004 | Science China(Physics,Mechanics & Astronomy)2004，47，1： | 1 |
| 3 | A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations显示文摘Dear Editor,Uncommon mutations in exons 18-21 of the epidermal growth factor receptor(EGFR)gene account for 10%–15%of all EGFR mutations when considered as a whole group[1,2].However,each variant confers heterogeneous clinical outcomes to different generations of EGFR tyrosine kinase inhibitors(TKIs)with G719X,L861Q,and/or S768I showing adequate sensitivity to EGFR inhibition[1–3].Osimertinib,based on its superior survival outcomes,has become the preferred first-line treatment for patients diagnosed with advanced non-small cell lung cancer(NSCLC)harboring common EGFR mutations[4];however,its efficacy in patients harboring G719X,S768I,and/or L861Q mutations was comparable or even inferior to Afatinib[5].Afatinib,a second-generation EGFR-TKI,has received approval for extended clinical indication in treating previously untreated patients with metastatic NSCLC harboring G719X,L861Q,and/or S768I based on the findings from the pooled analysis of three clinical trials(LUX-Lung 2/3/6)[2].The real-world clinical efficacy of Afatinib for treating this patient subset has been consistently demonstrated by two large retrospective studies[6,7].In China,chemotherapy remains a standard first-line treatment for this patient subset,with Afatinib available only as an off-label treatment option. | Pingli Wang Liming Cao Panwen Tian Shengxiang Ren Liyun Miao Chengzhi Zhou Yun Fan Yuping Li Dongqing Lv Xin Zhao Mei Yang Chaonan Zhu Bing Yu June Xu Yong Song Kai Wang | 2023 | Cancer Communications2023，43，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员